Health Care Systems
Health care systems organise the finance and delivery of health care. They vary by country, reflecting specific history, culture, and economics. To maximise coverage and efficiency they must evolve with changing demographics, needs, and technologies.
The trade deal and the trade-offs
27 October 2026
Grace Hampson is joined by Andy Briggs, Professor of Health Economics at LSHTM, and Adrian Towse, former Director of the Office of Health Economics, to explore…
The economic and health impact of UK CEiRSI: the UK Centre of Excellence for In-Silico Regulatory Science and Innovation
21 October 2026
Investing in the UK Centre of Excellence for in-silico Regulatory Science & Innovation (CEiRSI) could accelerate the adoption of in-silico technologies in the UK. Doing so could improve patient access to innovation, reduce NHS costs and strengthen the UK’s position as a global leader in in- silico technology and life sciences.
It’s not about working harder: rethinking NHS productivity
20 October 2026
Grace Hampson is joined by Anita Charlesworth, co-chair of the Health Foundation’s NHS Productivity Commission and Helen Hayes, Principal Economist at the Office of Health Economics…
Immunoglobulin sustainability in the United Kingdom
8 October 2026
Our report, commissioned and funded by argenx, looks at the challenges to Ig sustainability and assesses four potential policy responses.
Around the World in HTAs: Australia – The lucky country’s waiting game
5 October 2026
Australia’s HTA system was one of the world’s first, but outdated methods mean patients now wait an average of 466 days for subsidised access to new medicines. We look at the 2024 HTA Review and whether its reforms can close the gap.
Five unanswered questions from the UK’s Renewed Women’s Health Strategy
16 September 2026
The UK’s Renewed Women’s Health Strategy sets out an ambitious plan. But can the NHS deliver it?
Why President Trump’s generic drug tariffs are unlikely to fix America’s supply problem
13 August 2026
America’s dependence on foreign generic manufacturing is a real national security and supply concern. The vast majority of drug shortages in the U.S. are generics and shortages have increasingly burdened pharmacies across the country and disrupted care for the patients who rely on them, particularly those with chronic pain and cancer.
But President Trump’s most recent policy is unlikely to fix that problem. It’s far more likely to make American medicine cabinets less reliable, not more.
What the first EU JCA reveals about assessing precision oncology
28 July 2026
We explore how the first JCA provides insights into the longstanding methodological challenge of evidence generation and comparative assessment for precision medicine.
Net zero healthcare: Does HTA have a role to play?
7 July 2026
As part of those efforts, should environmental impacts be taken into consideration when assessing the value of new health technologies? Grace Hampson is joined by Koonal Shah, Associate Director and Head of Science Policy at NICE, and Chris Sampson,…